By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ProMetic Life Sciences Inc. 

8168 Montview Road

Mount-Royal  Quebec  H4P 2L7  Canada
Phone: 514-341-2115 Fax: 514-341-6227


SEARCH JOBS


Industry
Biotechnology

Segment
Pharmaceuticals





Company News
ProMetic Life Sci (PFSCF.PK) Release: New Data Presented By Prometic At American Diabetes Association's Scientific Sessions Validates PBI-4050's Positive Impact On Kidneys In Patients With Diabetes And Metabolic Syndrome 6/12/2017 8:10:58 AM
ProMetic Life Sci (PFSCF.PK) Presents New Data On PBI-4050 And Plasminogen At American Thoracic Society's 2017 International Conference 5/23/2017 7:32:20 AM
ProMetic Life Sci (PFSCF.PK) Announces The Closing Of The $25 Million Follow-On Financing From Structured Alpha LP, An Affiliate Of Thomvest Asset Management Inc. 4/28/2017 8:44:55 AM
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Shown To Reduce Liver Damage And Fibrosis In High-Fat Diet Induced Obesity And Metabolic Syndrome Mouse Model 4/20/2017 6:33:49 AM
ProMetic Life Sci (PFSCF.PK) Receives $9.5 Million Purchase Order From Multinational Client 4/7/2017 6:50:34 AM
ProMetic Life Sci (PFSCF.PK) Completes The Filing Of Its Plasminogen Biologics License Application ("BLA") With The U.S. FDA 4/5/2017 6:28:11 AM
ProMetic Life Sci (PFSCF.PK) Reports Its 2016 Fourth Quarter And Year End Highlights And Financial Results 3/31/2017 8:59:52 AM
ProMetic Life Sci (PFSCF.PK) To Report Its Fourth Quarter And Year-End 2016 Financial Results And Hold Conference Call / Webcast 3/23/2017 9:36:37 AM
FDA Grants Orphan Drug Designation To ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Drug For The Treatment Of Alström Syndrome 3/3/2017 7:29:11 AM
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Continues To Demonstrate Early Evidence Of Efficacy Following Completion Of Idiopathic Pulmonary Fibrosis Phase II Clinical Trial 2/22/2017 6:28:41 AM
12345678910...
//-->